title: Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.
abstract: BACKGROUND
  Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC). Long-term follow-up (LTFU) warrants further data.
  
  
  METHODS
  LTFU of patients, with stage II/III HER2+BC, treated by trastuzumab associated with docetaxel (Taxotere(®)) and/or carboplatin used as anthracycline-free PST was studied.
  
  
  RESULTS
  Among 135 patients, with a median follow-up of 48.3 months [95% confidence interval (CI) 45.3-52.4 months], the relapse-free survival (RFS) rate was 73.2% (95% CI 63.76% to 80.55%) while the overall survival (OS) rate was 91.87% (95% CI 84.23% to 95.90%). Adjuvant trastuzumab favorably influenced RFS in univariate analysis while the pathological nodal invasion unfavorably influenced RFS [Cox multivariate analysis (hazard ratio = 2.80, 95% CI 1.36-5.76, P = 0.0052)] and OS. Cardiac toxicity was minor (2.2% transient, reversible asymptomatic decrease in left ventricular ejection fraction).
  
  
  CONCLUSIONS
  This is the first report of LTFU showing that anthracycline-free trastuzumab-based PST combined either with docetaxel and/or carboplatin can achieve, without cardiac toxicity, very competitive results in terms of pathological complete response, RFS and OS, in HER2+BC. The choice of this schedule could be proposed to patients with vascular contraindication for anthracyclines or because patient's or physician's preference for a taxane-only schedule.
authors.affiliation: Departments of Medical Oncology, Medical Information, Pathology, CAC GF Leclerc, IFR 100, Dijon.
authors.forename: S
authors.initials: S
authors.lastname: Guiu
authors.forename: M
authors.initials: M
authors.lastname: Liegard
authors.forename: L
authors.initials: L
authors.lastname: Favier
authors.forename: I
authors.initials: I
authors.lastname: van Praagh
authors.forename: R
authors.initials: R
authors.lastname: Largillier
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: D
authors.initials: D
authors.lastname: Coeffic
authors.forename: L
authors.initials: L
authors.lastname: Moreau
authors.forename: F
authors.initials: F
authors.lastname: Priou
authors.forename: M
authors.initials: M
authors.lastname: Campone
authors.forename: J
authors.initials: J
authors.lastname: Gligorov
authors.forename: L
authors.initials: L
authors.lastname: Vanlemmens
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
authors.forename: L
authors.initials: L
authors.lastname: Arnould
authors.forename: B
authors.initials: B
authors.lastname: Coudert
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D018734:Genes, erbB-2; D006801:Humans
chemical_list: D000970:Antineoplastic Agents